Kidney cancer: overall survival is an unsuitable primary end point.
Final results of the CALGB 90206 and AVOREN trials have failed to demonstrate an overall survival benefit for bevacizumab plus interferon compared to interferon monotherapy in patients with metastatic renal cell carcinoma. Progression-free survival or objective response rate might be more suitable primary end points in phase III trials.
Di Lorenzo
Giuseppe
G
Buonerba
Carlo
C
D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000401:mortality; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination / Q000379:methods / Q000401:mortality; D023381:Endpoint Determination / Q000379:methods / Q000401:mortality*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality*; D015996:Survival Rate / Q000639:trends